Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT

Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis.

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02963129

Enrollment

Registered

2016-11-15

Start date

2017-06-30

Completion date

2017-12-31

Last updated

2016-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Hemorrhagic Telangiectasia, Epistaxis

Keywords

Hereditary Hemorrhagic Telangiectasia, Epistaxis

Brief summary

Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.

Detailed description

Hereditary hemorrhagic telangiectasia is a vascular dysplasia characterized by the development of mucocutaneous telangiectasia and arteriovenous malformations in organs such as brain, lung, liver and tube digestivo. Is considered a rare disease, although It means that there is a substantial underdiagnosis. The overall prevalence is 1/5000. Approximately 60% of the general population hosts strains of Staphylococcus aureus (S. aureus) intermittently and are called intermittent carriers, 20% represent persistent carriers harboring the same strain of S. aureus and 20% of the population are never carriers. On this concept, one might think that HHT patients in whom there is an active and pathological vascular remodeling that causes bleeding, and inflammation is a known activator of abnormal angiogenesis; reducing an inflammatory factor as microbial through the eradication of nasal S. aureus could be useful to reduce bleeding in this population, directly impacting on quality of life.

Interventions

OTHERPlacebo

Placebo ointment in the nose for 5 days

DRUGMupirocin

Mupirocin ointment in the nose for 5 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients over 18 years with possible or confirmed HHT as diagnostic criteria Curaçao. * Patients with nasal S. aureus colonization culture positive

Exclusion criteria

* Refusal to participate in the study or the informed consent process. * Hypersensitivity or contraindication for topical mupirocin.

Design outcomes

Primary

Measure	Time frame
Nosebleed by sadick scale	60 days

Secondary

Measure	Time frame
Prevalence of nasal colonization with Staphylococcus in patients with HHT by nasal cultive	60 days

Countries

Argentina

Contacts

Primary ContactMarcelo MS Serra, MD

marcelo.serra@hospitalitalino.org.ar49590200

Backup ContactCristina CE Elizondo, MD

cristina.elizondo@hospitalitalino.org.ar49590200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026